RemeGen Co. Ltd. A (688331.SHG)

RemeGen Co. Ltd. A stock price today, ATLAS forecast and fair value

Healthcare · Biotechnology · Shanghai Stock Exchange · China

CN¥94.64▼ -6.23%

Prices as of Oct 27, 2026 · CNY

ATLAS fair value

ATLAS has no fair value for this stock today.

Chance of rising in 1 month

47%

that it ends higher than today in 21 sessions

0%coin flip 50%100%

This is just the summary. See everything on RemeGen Co. Ltd. A in ATLAS

ATLAS's own quantitative analysis, all in one place.

Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
Officers and shareholdersWho runs the company and which funds hold its shares.
Customer and supplier mapWho it does business with, from its own filings.
ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
AlertsWe let you know when something changes in your stocks.

See everything included

Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
NewsThe latest on the company, in one place.
Crisis simulatorHow your portfolio would do in a crash like 2008.
Practice risk-free$10,000 in virtual money to invest at real prices.
Global screenerSearch US stocks and stocks from 47 countries with filters.

On RemeGen Co. Ltd. A

Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
Officers and shareholdersWho runs the company and which funds hold its shares.
Customer and supplier mapWho it does business with, from its own filings.
Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
NewsThe latest on the company, in one place.

And for you

ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
AlertsWe let you know when something changes in your stocks.
Crisis simulatorHow your portfolio would do in a crash like 2008.
Practice risk-free$10,000 in virtual money to invest at real prices.
Global screenerSearch US stocks and stocks from 47 countries with filters.

Get started →

Plans from €3.99 a month.

ATLAS's model gives RemeGen Co. Ltd. A a 47% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.

In half of the simulated outcomes the price ends between CN¥84.43 and CN¥104.08; in 9 out of 10, between CN¥70.14 and CN¥125.29. Estimated annual volatility is 58%.

Price, last 12 months (weekly close)

Key numbers

Market cap: CN¥57.0B
Market cap (USD): $8.6B
P/E ratio: 9.3
52-week high: CN¥157.80
52-week low: CN¥75.03
Revenue (12 months): CN¥8.0B
Gross margin: 93.9%
Operating margin: 84.5%
Net margin: 72.7%
Beta: 0.46

What this means

ATLAS does not publish a fair value for 688331.SHG right now, but it does show its odds of rising: close to a coin flip.

Over the last 52 weeks 688331.SHG has traded between CN¥75.03 and CN¥157.80. Today it is 40.0% below that high and 26% above its low.

On the business: net margin is 72.7%; it trades at 9.3 times earnings.

Its beta is 0.46: it tends to move less than the market.

About the company

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States.

Want to see everything about RemeGen Co. Ltd. A?

Get started →

Plans from €3.99 a month.

Comparable companies

Other companies in the same line of business:

Frequently asked questions

What does RemeGen Co. Ltd. A do?

What is the chance 688331.SHG goes up next month?

47%: close to a coin flip. In half of the simulated outcomes, 688331.SHG ends the month between CN¥84.43 and CN¥104.08.

How big is RemeGen Co. Ltd. A and what is its P/E ratio?

RemeGen Co. Ltd. A's market capitalization is CN¥57.0B. Its price-to-earnings (P/E) ratio is 9.3: you pay CN¥9.33 for each CN¥1.00 of yearly earnings.

How volatile is 688331.SHG?

ATLAS estimates annual volatility at 58%. In a typical month, half of the outcomes end between CN¥84.43 and CN¥104.08.

Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer